Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Details : Algernon Pharmaceuticals has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (“N,N-Dimethyltryptamine or DMT”), to Canadian-based Dalton Pharma Services.
Brand Name : AP-188
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 19, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : VIDO-InterVac
Deal Size : Undisclosed
Deal Type : Partnership
Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax
Details : Under this Partnership, Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : VIDO-InterVac
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Health Canada
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Dalton Expands Cannabinoids Capabilities
Details : Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 15, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Health Canada
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?